Incretin-Based Drugs Market Enters the Oral GLP-1 Era as Novo Nordisk and Eli Lilly Redefine Obesity Treatment, Access and Manufacturing Scale

July 17, 2026 - The global incretin-based drugs market is entering a new commercial phase as oral therapies expand competition beyond injectable GLP-1 products. DataM Intelligence estimates that the market reached US$26.69 billion in 2024 and will rise to US$42.42 billion by 2033, advancing at a 5.6% CAGR during 2025-2033. The market shifted materially on April 1, 2026, when the US Food and Drug Administration approved Eli Lilly's Foundayo, orforglipron, the first approved small-molecule GLP-1 pill for chronic weight management. That decision followed the January 5 US launch of Novo Nordisk's oral Wegovy, creating a direct contest between an oral peptide and a non-peptide small molecule.

Request For Exclusive Sample: https://www.datamintelligence.com/download-sample/incretin-based-drugs-market?kailas

2026 Official Developments in Oral and Next-Generation Incretin Therapies

The FDA approved Foundayo for adults with obesity or overweight with at least one weight-related condition, following an expedited national-priority review. Lilly said shipping began April 6, with retail and telehealth availability planned. Self-pay pricing started at US$149 for the lowest dose, while eligible Medicare Part D beneficiaries may be able to access the medicine for US$50 monthly beginning as soon as July 1, 2026.

Novo Nordisk entered 2026 with the first FDA-approved oral GLP-1 treatment for obesity. By June, the company reported more than three million Wegovy pill prescriptions, indicating that oral delivery can attract people previously outside prescription weight-management care. On July 15, Novo Nordisk also announced European Commission approval of the Wegovy pill, extending the emerging oral GLP-1 contest beyond the United States.

Pipeline competition is accelerating. AstraZeneca advanced elecoglipron, an investigational oral small-molecule GLP-1, into Phase III after reporting Phase IIb obesity and diabetes results in June. Roche's April 2026 pipeline continues to list CT-996, a once-daily oral small-molecule GLP-1 candidate for obesity and type 2 diabetes.

Oral Economics Reshapes the Competitive Model

The obesity pill market is not simply replacing injections. Oral semaglutide remains peptide-based and carries formulation, absorption and high-dose manufacturing considerations. Small molecules such as orforglipron and elecoglipron may offer easier production scaling than peptides while avoiding sterile pen assembly and injection-device bottlenecks. Injectable peptides, however, retain weekly dosing and established prescriber familiarity. AstraZeneca has specifically identified scalability and the absence of food or fasting restrictions as potential advantages of its investigational small-molecule platform.

Request for Customized Report as per your Business Requirements: https://www.datamintelligence.com/customize/incretin-based-drugs-market?kailas

Growth Drivers and Market Counter-Risks

Growth in the incretin-based drugs market is being supported by the increasing prevalence of obesity and type 2 diabetes, greater recognition of obesity as a chronic disease and expanding evidence connecting metabolic treatment with wider health outcomes.

Oral treatments could increase the addressable population by reaching patients who are unwilling or unable to begin injectable therapy. They may also support earlier intervention in primary-care settings, where prescribing and distribution simplicity can influence treatment uptake.

The market nevertheless faces meaningful risks. Gastrointestinal adverse events, treatment discontinuation, safety monitoring requirements and inconsistent insurance coverage remain barriers to sustained adoption.

Lower cash prices may improve accessibility but could also intensify competition and place pressure on net pricing across the GLP-1 category. Payers are likely to evaluate long-term adherence, healthcare-cost reductions and real-world outcomes rather than relying only on headline weight-loss results.

Growth Drivers and Counter-Risks

Demand is being supported by rising obesity and type 2 diabetes prevalence, growing recognition of obesity as a chronic disease and interest in cardiometabolic outcomes beyond weight reduction. Oral therapies may widen the addressable population among people unwilling to begin injections, while multi-agonist programmes are expanding the broader metabolic therapeutics pipeline.

Commercial expansion is not guaranteed. Gastrointestinal adverse events, discontinuation, boxed warnings, safety monitoring and uneven reimbursement remain important barriers. Lower cash prices may improve access but intensify pressure on net pricing. Payers will increasingly examine treatment persistence, total health outcomes and real-world value rather than weight-loss percentages alone.

Decision-Useful Market Segmentation

DataM Intelligence segments the incretin-based drugs market by drug class into DPP-4 inhibitors and GLP-1 analogues; by route into oral and injectable therapies; and by channel into hospital, retail and online pharmacies.

Strategic analysis now also requires segmentation by peptide versus small molecule, obesity versus diabetes indication, single agonist versus incretin combination therapy, and traditional pharmacy versus digital distribution. These distinctions will increasingly influence manufacturing investment, product positioning and reimbursement negotiations.

Country Opportunity Outlook

United States: The US is the immediate commercial proving ground, combining FDA approvals, telehealth distribution, direct-pay models and emerging Medicare pathways. Competition will focus on formulary placement, patient acquisition costs and supply reliability.

Japan: Japan is strategically important for diabetes-focused incretin adoption and future obesity indications. Lilly included Japan in the global ATTAIN-1 programme and has submitted orforglipron in more than 40 countries. Local approval, pricing and reimbursement will determine the pace of oral uptake.

Germany: European Commission approval of the Wegovy pill creates a route toward German market entry. National reimbursement assessment and negotiated pricing will determine whether oral GLP-1 therapy expands the treated population or shifts existing users between formulations.

China: China combines a substantial metabolic-disease burden with expanding local development and manufacturing capabilities. Lilly's global trials included China, while AstraZeneca's 2026 collaboration with CSPC preserved Greater China rights for CSPC across several metabolic programmes, emphasizing the importance of local commercialization structures.

Purchase This Exclusive Report: https://www.datamintelligence.com/buy-now-page?report=incretin-based-drugs-market?kailas

Strategic Company Profiles

Novo Nordisk is defending its incretin leadership through oral Wegovy, injectable semaglutide and next-generation combinations. Its advantages include peptide expertise, brand recognition and established obesity-care infrastructure.

Eli Lilly now pairs injectable tirzepatide with Foundayo and a broader next-generation pipeline. Orforglipron adds a small-molecule platform that could diversify GLP-1 manufacturing and distribution while intensifying pricing competition.

Roche, profiled as a pipeline comparator, is developing an obesity portfolio that includes CT-996. Its opportunity is to differentiate through molecular design and combinations rather than compete only on delivery format.

AstraZeneca, a DataM-listed market participant, has advanced elecoglipron toward Phase III while developing monotherapy and combination strategies spanning obesity, diabetes, cardiovascular and kidney outcomes.

"The oral GLP-1 era changes the market from a product race into a platform race spanning chemistry, capacity, access, adherence and reimbursement," said a DataM Intelligence spokesperson. "Durable positions will be built by companies that connect differentiated clinical evidence with scalable supply and affordable patient access."

The incretin-based drugs market is entering a period of broader therapeutic choice but sharper execution risk. DataM Intelligence provides customized analysis covering pipeline benchmarking, manufacturing-capacity scenarios, molecule-class segmentation, country launch attractiveness, competitive positioning and reimbursement pathways for oral GLP-1 drugs and next-generation incretin therapies.

Contact Us:
Sai Kiran
Business Development Manager
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, Lalitha Nagar, Habsiguda,
Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com

About DataM Intelligence
DataM Intelligence is a global market research and business intelligence firm delivering actionable insights across healthcare, pharmaceuticals, chemicals, energy, technology, food, and industrial sectors. Through syndicated reports, custom research, consulting, and competitive intelligence services, the company helps organizations identify growth opportunities, navigate market challenges, and make informed strategic decisions in over 50+ countries worldwide.

This release was published on openPR.